

NHLBI SBIR Program

Translating Discovery to the Marketplace

Kurt Marek, PhD

Program Director, SBIR Coordinator

Office of Translational Alliances and Coordination
DERA, NHLBI





Genentech
IN BUSINESS FOR LIFE



MedImmune



illumina[®]

\$75 million



National Heart Lung and Blood Institute

Outline

- Background
- Funding Opportunities
- Resources
- Reauthorization

SBIR

STTR



Purpose



SBC: >50%

Effort


SBC: 40%
RPI: 30%

SBC

PI


Either

SBIR/STTR: Three-Phases




PHASE I

- Feasibility studies
- \$150K for 6-months



PHASE II

- Full research and development
- \$1-2M for 2-years
- Commercialization plan required



PHASE III

- Commercialization stage
- Use of non-SBIR/STTR Funds

Investigator Initiated Grants Omnibus Solicitation (PA-12-088, PA-12-089)

**We encourage applications for any topic
within the NHLBI mission**


Due December 5, 2012, April 5 2013, August 5, 2013

http://www.nhlbi.nih.gov/funding/sbir/funding/omnibus_grant_solicitation.htm

Targeted Funding Opportunities

- SBIR-Technology Transfer
- SBIR Bridge Award Program

NHLBI Laboratories



- Nanotechnology
- Imaging
- Glycobiology
- miRNA
- Interventional cardiology
- Biophysics
- Gene therapy
- Asthma


SBIR Technology Transfer (SBIR-TT)

- Investigator Initiated
 - Any NHLBI Intramural technology
 - techfinder.nhlbi.nih.gov
 - Grant mechanism
 - [PA-11-347](#)
- Requests for Proposals (RFPs)
 - Specific technologies identified by NHLBI
 - Contract mechanism

Licensing (applies to both types)


- Awardees automatically receive non-exclusive research and development license
- Awardees encouraged to apply for exclusive commercialization license

SBIR: Three-Phases



PHASE I


- Feasibility studies
- \$150K for 6-months



PHASE II

- Full research and development
- \$1-2M for 2-years
- Commercialization plan required

SBIR Bridge Award



PHASE III

- Commercialization stage
- Use of non-SBIR/STTR Funds

Phase IIB Bridge Award

- \$1 million per year for 3 years
- Encourages third-party investment equal to or greater than the NHLBI investment
- Supports products that need FDA clearance/approval
- [RFA-HL-13-016](#)

Phase II grants or contracts from any NIH Institute/Center or any Federal agency (e.g. NSF, DoD) are eligible

Annual Contract Topics (PHS2013-1)

- New Methods to Detect and Assess Myocardial Fibrosis
- Evaluating Obstructive Sleep Apnea Dental Device Treatment Compliance
- Improving Safety and Efficacy of Red Blood Cells for Transfusion
- Dedicated Pediatric Cardiac MRI Receive Coils
- MRI Myocardial Biopsy Forceps
- Passive MRI Guidewire
- Transthoracic Cardiac Access Ports and Closure Devices
- Bioabsorbable Stents for Pediatric Pulmonary Artery Stenosis and Aortic Coarctation
- Fluorescent Nanodiamonds for In Vitro and In Vivo Biological Imaging

www.nhlbi.nih.gov/funding/sbir/funding/contract_topics/contracttopics.htm

Due November 13, 2012

Resources

- NIH Niche Assessment Program
 - Phase I companies
 - Market analysis
- NIH Commercialization Assistance Program
 - Phase II companies
 - Personalized help
- NHLBI Regulatory Assistance

Reauthorization

- Set-aside increase: 2.8% to 3.65% in 2017
- VC, hedge fund, private equity participation
- Phase II from another agency
- Switch from SBIR to STTR and vice versa

Contact Us

- kurt.marek@nih.gov
- 301-496-2149
- <http://www.nhlbi.nih.gov/funding/sbir/index.htm>



MedImmune

